Aprea Therapeutics, Inc. (APRE)
$0.58-3.33%Close
SELLCRISIS · day 10
Snapshot
- Call
- SELL
- Regime
- CRISISday 10
- Alignment
- ALIGNED BEAR
- 1 week
- -3.3%-2.4% vs SPY
- 1 month
- -25.6%-27.0% vs SPY
- Market cap
- $3.8M
- P/E
- negindustry 14.0
- P/B
- 0.8
- EV/EBITDA
- 2.8
- Short % float
- 10.5%
- Days to cover
- 2.5
- Short change
- -11.4%
- Consensus
- Buy4 buy · 2 hold · 2 sell
Signal: Score, Composite, ATR trend, HiLo flip, Coil, Exhaustion, Topping · Technicals (EMA stack, slope, squeeze, stochastic, MACD-Z, DI+) · Price & returns: 3 months, Year to date, 1 year
Price & returns: 3 years, 5 years
Performance (Q-Score, Sharpe, Sortino, Calmar, CAGR, drawdown, alpha)
Signal evidence
Best ComboVALIDATED · V5
ENTER · HOLD · EXIT · WAITOne next-open action from five signal families, published only when the held-out edge survives 20 bps costs.
Today's action with its out-of-fold profit factor, trade count and family votes.
White ArrowFULL HISTORY
SELL
Directional consensus stays BUY or SELL until the model reverses; trades fill next session open.
Profit factor0.3
Trades42
RegimeFULL HISTORY
CRISIS
BULL or RECOVERY stays invested; BEAR or CRISIS exits at the next session open.
Profit factor and trade count for holding this symbol only in BULL or RECOVERY.
ExhaustionNOW
Whether buyers or sellers are stretched today, the latest release and its strength.
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company
About
Aprea Therapeutics, Inc. (APRE). Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Back…
SEC filingsCIK 1781983
Profile
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUS
CEOOren Gilad
IPOOct 3, 2019
Employees8
Shares outstanding6.5M
Float4.8M
Free float74.7%
Websiteaprea.com
Key executives
- Oren GiladCo-Founder, Chief Executive Officer, President and DirectorUSD 599K
- John HamillSenior Vice President, Chief Financial Officer, Principal Accounting Officer & SecretaryUSD 461K
- Lars AbrahmsenSenior Vice President & Chief Scientific Officer
- Michel AfarganHead of Pharmacology Development
- Eugene KennedyChief Medical Advisor
- Brian WileySenior Vice President of Corporate Development & Strategy
Fundamentals
SCORES & PROFILE
- FUND
- 0
- VALUE
- 9
- GROWTH
- 17
- GARP
- 0
- TYPE
- Balanced
- COV
Composite of Value · Growth · GARP
ROIC-28.0%
REV YoY-100.0%
ROE-46.7%
EPS YoY-
ROA-29.1%
GROSS0
OP0
NET0
VALUATION
P/E TTM-0.54
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B0.81
P/FCF-
EV/EBITDA2.77
EV/EBIT-
FCF YIELD-
TRUE FCF YLD-
PEG-
BUYBACK0.00%
Risk
INT COV∞
D/E-
ALTMAN Z-10.07
CURR RATIO13.55
ND/EBITDA-
NET INCOME (TTM) < 0
